title: Paving the critical path of drug development: the CDER perspective.
abstract: Improving the science of drug development and regulation is important in fulfilling the public health mission of the US Food and Drug Administration (FDA). A decade on from the launch of the Critical Path Initiative, the FDA's Center for Drug Evaluation and Research (CDER) is now participating in more than 20 science-driven consortia to achieve this goal.
authors.affiliation: Director, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue Silver Spring, Maryland 20993-0002, USA.
authors.forename: Janet
authors.initials: J
authors.lastname: Woodcock
mesh_terms: D019091:Critical Pathways; D017277:Drug Approval / Q000379:methods*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration